NCT05397184 - Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

February 28, 2025

Conditions

Relapsed/Refractory T-cell Acute Lymphoid Leukaemia

Interventions

BIOLOGICAL

Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)

Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months

Trial Locations (1)

WC1N 1EH

RECRUITING

Ilyas Ali, London